People

Celebrities and Royals from around the world. Right on schedule.

News

Daily news and events, covered by our international photographers.

Features

Odd, funny and touchy images. Be amazed.

Styling

Fashion and design trends.

Portrait

Premium Portraiture.

Reportage

In-depth Coverage.

Creative

Selected stock imagery.

Dukas Bildagentur
request@dukas.ch
+41 44 298 50 00

Your search:

25 result(s) in 0.02 s

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629658_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629666_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629659_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629679_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured playing on his drum set.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629681_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured playing on his drum set.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629667_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629668_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629664_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629662_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629665_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629672_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with mum Kristina Gray and pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629661_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629660_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629663_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629675_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629670_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629669_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629671_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629677_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629678_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629680_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629676_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629674_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629673_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.

     

  • ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    DUKAS_118629682_EYE
    ‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
    ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
    Sanuel is pictured with pet dog Hamish.
    Photo by Fabio De Paola** Clearance required prior to publication**
    © Fabio De Paola / Guardian / eyevine

    Contact eyevine for more information about using this image:
    T: +44 (0) 20 8709 8709
    E: info@eyevine.com
    http://www.eyevine.com
    (FOTO: DUKAS/EYEVINE)
    © Guardian / eyevine. All Rights Reserved.